Stereotaxis Inc (STXS) Stock Forecast & Price Target

Stereotaxis is viewed positively because its 2Q26 results showed recurring revenue of $6.2 million, including over $1 million of robotic catheter sales and more than 270% sequential growth in that category, while new products like MAGiC and Synchrony began to convert regulatory wins into early commercial traction. Although system revenue fell to $1.5 million and no robotic systems were placed in the quarter, management still expects >$1 million in capital sales in both 3Q and 4Q, 2-5 GenesisX placements this year, and improving catheter output as supply constraints ease. The longer-term appeal rests on a razor/razor blade model supported by 100+ dedicated Niobe user accounts, a projected move toward cash-flow profitability in 1H27, and an estimated 2027 sales base of $46.5 million to $47 million with roughly 30%+ top-line growth.

Stereotaxis is facing a weak fundamental profile because revenue has been inconsistent, with 1Q revenue of $6.3M and Q2 revenue of $7.7M both missing expectations, while system sales fell 32.8% year over year in 1Q and 51% in Q2, underscoring dependence on lumpy capital purchases. Although recurring revenue is more resilient, it remains too small to offset operational pressure, as adjusted operating losses of $2.1M in Q2 and $9.8M of 1Q operating expenses highlight a business that is still not generating durable cash flow. The negative outlook is reinforced by stated risks around the company’s ability to fund operations, slow hospital adoption, supply constraints on MAGiC, potential technology and IP lag, and concentration of influence among principal stockholders and key management.